Concomitant mutation

Xem 1-2 trên 2 kết quả Concomitant mutation

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study

Non-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of tyrosine kinase inhibitors (TKIs), and may benefit from a combination regimen preferentially. The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a reallife setting.

11p vischultz 20-10-2023 2 1 Download

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been approved for treatment of metastatic melanomas with a BRAF p.V600E mutation. The clinical significance of non-codon 600 mutations remains unclear, in part, due to variation of kinase activity for different mutants.

10p vimoscow2711 29-08-2020 18 1 Download